The short version of Translational gap fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-23 and is reviewed periodically as new material appears.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The white shark is an obligate ram ventilator; to breathe, it must swim constantly so water flows through its gills. Over 95% of the shark's musculature is white, fast-twitch muscles, which allows it to move in quick sprints, particularly when ambushing prey. The remaining dark, slow-twitch muscles carry oxygen to power the shark while at cruising speed. The white shark has a large, double-lobed liver that can be almost 30% of its body weight and stores lipids, fatty acids, and oils. The liver helps keep the shark from sinking, as the oil is six times more buoyant than the surrounding water. The lipids and fatty acids provide the shark with energy for travel and are important for reproduction and growth. One study concluded that a white shark liver is more energy-rich than whale blubber. White sharks appear to have strong immune systems and can tolerate high amounts of toxic heavy metals like mercury and arsenic in their blood, more so than many other vertebrates. They are also documented to heal relatively quickly from even severe wounds, and the species's genome shows "positive selection in key genes involved in the wound-healing process". White sharks use a system of blood vessels to warm up portions of their body (regional endothermy), which allows them to be active and hunt in cool waters. In this complex blood vessel system, known as a rete mirabile, warm blood generated from the dark muscles is constantly supplied to other parts of the body.
The three substrates of this enzyme are benzaldehyde, oxidised nicotinamide adenine dinucleotide phosphate (NADP+), and water. Its products are benzoic acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is benzaldehyde:NADP+ oxidoreductase. Other names in common use include NADP+-linked benzaldehyde dehydrogenase, and benzaldehyde dehydrogenase (NADP+). This enzyme participates in benzoate degradation via hydroxylation and toluene and xylene degradation.
==== Actions ==== The 2C drugs act as agonists of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. They are partial agonists of the serotonin 5-HT2A receptor. Most of the 2C drugs have much lower affinity for the serotonin 5-HT1A receptor than for the serotonin 5-HT2A receptor. Most of the 2C drugs have also shown about 5- to 15-fold higher affinity for the serotonin 5-HT2A receptor over the serotonin 5-HT2C receptor and about 15- to 100-fold higher affinity for the serotonin 5-HT2A receptor over the serotonin 5-HT1A receptor. The psychedelic effects of the 2C drugs are thought to be mediated specifically by activation of the serotonin 5-HT2A receptor. Unlike many other phenethylamines, 2C drugs, including 2C-C, 2C-D, 2C-E, 2C-I, and 2C-T-2 among others, are inactive as monoamine releasing agents and reuptake inhibitors. Most of the 2C drugs are agonists of the rat and mouse trace amine-associated receptor 1 (TAAR1). However, most are inactive as agonists of the human TAAR1. The 2C drugs show very weak monoamine oxidase inhibition, including of monoamine oxidase A (MAO-A) and/or monoamine oxidase B (MAO-B).
Breast milk contains several anti-infective factors such as bile salt stimulated lipase (protecting against amoebic infections) and lactoferrin (which binds to iron and inhibits the growth of intestinal bacteria). Exclusive breastfeeding until six months of age helps to protect an infant from gastrointestinal infections in both developing and industrialized countries. The risk of death due to diarrhea and other infections increases when babies are either partially breastfed or not breastfed at all. Infants who are exclusively breastfed for the first six months are less likely to die of gastrointestinal infections than infants who switched from exclusive to partial breastfeeding at three to four months. During breastfeeding, approximately 0.25–0.5 grams per day of secretory IgA antibodies pass to the baby via milk. This is one of the important features of colostrum. The main target for these antibodies are probably microorganisms in the baby's intestine. The rest of the body displays some uptake of IgA, but this amount is relatively small. Maternal vaccinations while breastfeeding are safe for almost all vaccines. Additionally, the mother's immunity obtained by vaccination against tetanus, diphtheria, whooping cough, and influenza can protect the baby from these diseases, and breastfeeding can reduce the fever rate after infant immunization. However, smallpox and yellow fever vaccines increase the risk of infants developing vaccinia and encephalitis.
İstivayı özler gözüm, (My eye seeks out repose,) Seb'al-mesânîdir yüzüm, (my face is the 'oft repeated seven (i.e. the Sura Al-Fatiha),) Ene'l-Hakk'ı söyler sözüm, (My words proclaim "I am the Truth",) Miracımız dardır bizim, (Our ascension is (by means of) the scaffold,) Haber aldık muhkemattan, (We have become aware through the "firm letters",) Geçmeyiz zâttan sıfattan, (We will not abandon essence or attributes,) Balım nihan söyler Hakk'tan, (Balım speaks arcanely of God) İrşâdımız sırdır bizim. (Our teaching is a mystery.) There is no official canon of Bektashism as the central tenet of Bektashism is "seeing the 72 nations in one eye" (which means all nations and religions are inherently same) and that "batin is more important than zahir", however there are generally accepted books attributed to the founding of the order. Makalat (The Articles), where the concept of four gates (sharia, tariqa, marifa, haqiqa) originate from, is according to Bektashis it was written by Haji Bektash Veli himself and by his order translated into local languages from Arabic in oral form and therefore in this form it is considered a central scripture. Another important book of Bektashism is Velayetname (The Book of Walayah), also attributed to Haji Bektash Veli himself, which gives a poetic account of the origin of the sect and the brief history of the faith as it spread through Anatolia. Other important writings are poetry of anonymous poet "Virani", the books of Kaygusuz Abdal, the Erkannames (Guiding Principles) and the poetry attributed to Shah Ismail.
Sources: en.wikipedia.org
The 2nd Black Watch, with its Rhodesian contingent, took part in the unsuccessful Allied defence of Crete in May–June 1941, then joined the garrison at Tobruk in August 1941. No. 237 (Rhodesia) Squadron was re-equipped with Hawker Hurricanes the following month.
A large meta-analysis has shown that white adipose tissue cell size is dependent on measurement methods, adipose tissue depots, age, and body mass index; for the same degree of obesity, increases in fat cell size were also associated with the dysregulations in glucose and lipid metabolism.
During October and November 2005, Wenger became embroiled in a war of words with Chelsea manager José Mourinho. Mourinho accused Wenger of having an "unprofessional obsession" with Chelsea and labelled him a "voyeur". Mourinho was quoted as saying, "He's worried about us, he's always talking about us – it's [always] Chelsea". Wenger responded by pointing out he was only answering journalists' questions about Chelsea, and described Mourinho's attitude as "disrespectful". Mourinho later apologised and clarified that he regretted his "voyeur" comment; Wenger accepted the apology. In 2014, Mourinho reopened his feud with Wenger by calling him a "specialist in failure". This was in response to Wenger's comments that Chelsea were favourites for the Premier League and managers did not want to take responsibility if they failed to win the title. Wenger said Mourinho's comments were "silly and disrespectful" and had embarrassed Chelsea. When asked if he regretted his remark, Mourinho replied: "You have to ask him if he regrets the comments he made". In October 2014, during a Premier League match between Arsenal and Chelsea, Wenger was involved in a touchline spat with Mourinho. Wenger later apologised for his behaviour. Wenger has directed his anger towards referees when decisions have not gone his team's way. In August 2000, he was charged with "alleged threatening behaviour and physical intimidation" towards fourth official Paul Taylor, after Arsenal's 1–0 defeat at Sunderland on the opening day of the 2000–01 season.
In 1906, Hahn returned to Germany, where Fischer placed at his disposal a former woodworking shop (Holzwerkstatt) in the basement of the Chemical Institute to use as a laboratory. Hahn equipped it with electroscopes to measure alpha and beta particles and gamma rays. In Montreal these had been made from discarded coffee tins; Hahn made the ones in Berlin from brass, with aluminium strips insulated with amber. These were charged with hard rubber sticks that he rubbed against the sleeves of his suit. It was not possible to conduct research in the wood shop, but Alfred Stock, the head of the inorganic chemistry department, let Hahn use a space in one of his two private laboratories. Hahn purchased two milligrams of radium from Friedrich Oskar Giesel, the discoverer of emanium (radon), for 100 marks a milligram (equivalent to €700 in 2021), and obtained thorium for free from Otto Knöfler, whose Berlin firm was a major producer of thorium products. In the space of a few months Hahn discovered mesothorium I (radium-228), mesothorium II (actinium-228), and – independently from Boltwood – the mother substance of radium, ionium (later identified as thorium-230). In subsequent years, mesothorium I assumed great importance because, like radium-226 (discovered by Pierre and Marie Curie), it was ideally suited for use in medical radiation treatment, but cost only half as much to manufacture. Along the way, Hahn determined that just as he was unable to separate thorium from radiothorium, so he could not separate mesothorium I from radium.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.